Skip to content
Open access

Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer

Aug 2026 · Nature Communications · Vol 17 · 0 citations · 168 references
Medicine

TL;DR

Overall, tumor-invaded LNs and tumors coordinate the generation and maintenance of tumor-reactive CD4+ lineages, identifying highly plastic follicular T cells as therapeutic checkpoints to reinforce anti-tumor responses.

Abstract

Tumor-invaded lymph nodes (LNs) are critical but poorly studied hubs of anti-tumor immunity. Using single-cell transcriptome, clonotype, and chromatin profiling, we analyze CD4 + T cells from blood, LNs, and tumors of NSCLC patients. LNs and tumors are enriched in follicular regulatory T cells (Treg-Tfr), follicular-like conventional T cells (Tconv-Tfh and Tconv-CXCL13), and tissue-resident Tregs (Treg-Trm). These populations are predicted to share a transcriptional program of activation and tissue adaptation, driven by BATF. Additionally, these subsets show extensive LN-tumor clonal sharing, indicating recirculation, and are enriched in transcriptional signatures of tumor reactivity. Treg-Tfr cells function as progenitors bifurcating into Treg-Trm or ex-Tregs with a Tfh-like CXCL13+ effector phenotype. Follicular subsets in LNs and tumors are transcriptionally and epigenetically similar and localize in germinal-center-like niches. Overall, tumor-invaded LNs and tumors coordinate the generation and maintenance of tumor-reactive CD4+ lineages, identifying highly plastic follicular T cells as therapeutic checkpoints to reinforce anti-tumor responses. To provide additional insights into the biology of CD4 + T cells in cancer, here the authors report a multi-omics analysis of CD4 + T cells from matched blood, tumor invaded lymph nodes (LNs), and tumor tissues of patients with non-small cell lung cancer, showing that tumor-invaded LNs and tumors harbor clonally linked and plastic follicular CD4+T cell subsets.

Read PDF

Similar papers

Open access Aug 2026

Molecular heterogeneity and clonal origin of CCR8+ effector regulatory T cells in human cancer

CD4+CD25+FOXP3+ regulatory T cells (Treg) are highly activated in tumors and promote disease progression. Specific, universal targeting of these effector Treg cells is limited by the lack of a conserved signature across human cancers and information on their origin. Here we combine analysis of single-cell RNA-sequencin...

J. Swatler, S. Puccio, Emanuele Voulaz et al. · 0 citations
Open access Sep 2026

Tissue resident CD4+ memory T-cells mark response to immune checkpoint inhibition in high-grade glioma

Background Immune checkpoint inhibitors (ICI) are efficacious in many solid tumors, but response in glioma is restricted to a small subgroup. The determinants of response and resistance to ICI remain poorly understood. Methods Here we exploit a syngeneic hypermutated high-grade glioma model with dichotomous response to...

Verena Turco, Chin-Leng Tan, D. Agardy et al. · 0 citations
Open access Oct 2026

Integrated spatial and single-cell transcriptomics uncover IFI6⁺ regulatory T-cells and SPP1⁺ macrophages immunosuppressive niches in colorectal cancer.

This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.

Dominika Miroszewska, Shi-Yang Song, Víctor Urbiola-Salvador et al. · 0 citations
Open access Sep 2026

Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.

Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) induces durable responses in metastatic melanoma, yet the clonal and transcriptional dynamics governing tumor-reactive T cell fate during ex vivo expansion and after transfer remain poorly understood. Here, we perform longitudinal single-cell RNA and T ce...

M. Sandholzer, Clara Serger, Alessia G. Liner et al. · 0 citations
Review Open access Aug 2026

Stem-like CD4 T cells in tumors: an emerging framework for antitumor immunity

stem-like CD4 biology is presented as an emerging framework and established observations from working models are distinguished and established observations from working models are distinguished.

Jia-Xiang Xu, Yun-Chao Yang, Jun Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.